/ALLK
ALLK Stock - Allakos Inc.
Healthcare|BiotechnologyNASDAQ
$0.33+0.22%
+$0.00 (+0.22%) • May 15
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+22385.6%upside
Target: $74.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALLK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.33 – $0.33
TARGET (TP)$74.00
STOP LOSS$0.30
RISK/REWARD1:2531.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.14
52W High$1.56
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-7,724,000 | $-6,141,000 | $-9,975,000 | $-4,880,000 | $-2,339,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-122,225,000 | $-196,056,000 | $-322,429,000 | $-271,475,000 | $-157,057,000 |
| Net Income | $-115,818,000 | $-185,701,000 | $-319,952,000 | $-269,860,000 | $-153,480,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.30 | $-2.14 | $-5.06 | $-5.01 | $-3.10 |
Company Overview
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
57%
Hold / Neutral
2
29%
Sell / Underperform
1
14%
Analyst Consensus🟡 Mixed
4 Bullish3 Neutral/Bearish
Price Targets
$9
Average Target
↑ 2508.1% Upside
Now
$2
Low
$9
Average
$22
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 17th 2024 | Jefferies | Downgrade | Hold | $1.5← $6 |
| January 16th 2024 | Cantor Fitzgerald | Downgrade | Neutral | - |
| December 18th 2023 | William Blair | Upgrade | Outperform | - |
| December 8th 2023 | Jefferies | Resumed | Buy | $6← $9 |
| September 27th 2023 | JMP Securities | Initiation | Mkt Outperform | $11 |
| May 12th 2023 | Jefferies | Upgrade | Buy | $9← $6 |
| March 7th 2023 | Piper Sandler | Initiation | Overweight | $22 |
| September 12th 2022 | SMBC Nikko | Downgrade | Underperform | $2 |
Earnings History & Surprises
ALLKBeat Rate
33%
Last 18 quarters
Avg Surprise
-5.0%
EPS vs Estimate
Beats / Misses
6/11
1 met exactly
Latest EPS
$-0.29
Q2 2025
EPS Surprise History
Q3 23
+16.3%
$-0.41vs$-0.49
Q4 23
-13.0%
$-0.52vs$-0.46
Q1 24
-34.0%
$-0.71vs$-0.53
Q2 24
-22.0%
$-0.50vs$-0.41
Q3 24
+6.3%
$-0.30vs$-0.32
Q4 24
+4.5%
$-0.21vs$-0.22
Q1 25
+102.0%
$0.00vs$-0.21
Q2 25
-11.5%
$-0.29vs$-0.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 4, 2025 | — | — | — | — |
Q3 2025 | Aug 6, 2025 | $-0.24 | — | — | — |
Q2 2025 | May 7, 2025 | $-0.26 | $-0.29 | -11.5% | ✗ MISS |
Q1 2025 | Mar 12, 2025 | $-0.21 | $0.00 | +102.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.32 | $-0.30 | +6.3% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.41 | $-0.50 | -22.0% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.53 | $-0.71 | -34.0% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.46 | $-0.52 | -13.0% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.49 | $-0.41 | +16.3% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.49 | $-0.49 | 0.0% | = MET |
Q1 2023 | Mar 6, 2023 | $-0.56 | $-0.50 | +10.7% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.78 | $-0.53 | +32.1% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.87 | $-0.90 | -3.4% | ✗ MISS |
Q2 2022 | May 6, 2022 | $-1.71 | $-3.60 | -110.5% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-1.34 | $-1.73 | -29.1% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-1.12 | $-1.16 | -3.6% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-1.06 | $-1.07 | -0.9% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-0.78 | $-1.04 | -33.3% | ✗ MISS |
Q1 2021 | Mar 1, 2021 | $-0.85 | $-0.86 | -1.2% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ALLK
What is ALLK's current stock price?
Allakos Inc. (ALLK) is currently trading at $0.33 per share. The stock has moved +0.22% today.
What is the analyst price target for ALLK?
The average analyst price target for ALLK is $74.00, based on 1 analyst.
What sector is Allakos Inc. in?
Allakos Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALLK's market cap?
Allakos Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does ALLK pay dividends?
No, Allakos Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGTC
Applied Genetic Technologies Corporation
$0.39
0ANGN
Angion Biomedica Corp.
$1.00
Mkt Cap: $0.0B
ELEV
Elevation Oncology, Inc.
$0.36
Mkt Cap: $0.0B
FRLN
Freeline Therapeutics Holdings plc
$6.49
Mkt Cap: $0.0B
HARP
Harpoon Therapeutics, Inc.
$23.01
Mkt Cap: $0.9B
KA
Kineta, Inc.
$0.57
Mkt Cap: $0.0B
LIANY
LianBio
$0.11
Mkt Cap: $0.0B
MRNS
Marinus Pharmaceuticals, Inc.
$0.55
Mkt Cap: $0.0B
MTCR
Metacrine, Inc.
$0.58
0ODTC
Odonate Therapeutics, Inc.
$22005.00
Mkt Cap: $8.0B
Explore stocks similar to ALLK for comparison